Clincosm LogoSign in Get a demo

Clinico-pathologic Correlative Study of 3T Magnetic Resonance Spectroscopy in the Localization of Prostate Cancer

Sponsor
AHS Cancer Control Alberta (Other)
Overall Status
Completed
CT.gov ID
NCT00310479
Collaborator
Cross Cancer Institute (Other)
16
Enrollment
1
Location
21
Duration (Months)
0.8
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

We seek to develop an advanced imaging approach to identifying and localizing prostate cancer. We believe that high field MRI (magnetic resonance imaging) has the potential to do this and we will endeavor to prove this by having patients with prostate cancer pre-operatively undergo a technique called magnetic resonance spectroscopy. After surgery, the microscopic locations of cancer will be compared with the pre-operative images to assess how well the imaging technique succeeds.

Condition or Disease Intervention/Treatment Phase
  • Device: Magnetic Resonance Spectroscopy (3Tesla)
 N/A

Detailed Description

The proposed research is enormously relevant to the clinical understanding of early prostate cancer. We propose to test to see whether characteristic patterns of invivo 3T MRSI associated metabolites can be identified in correlation with clinically active tumor reserved on histopathologic analysis of resected specimens. We also plan to demonstrate that 3T MR spectra of prostate cancer will allow for more detailed metabolic assessment with higher sensitivity, specificity and accuracy and publish results established from MR spectra using 1.5T MR units. Functional imaging (eg. molecular imaging such as this) is felt to be the clinical wave of the future for cancer imaging, and if successful, will assume a very major role in the detection, assessment, treatment planning and delivery of drugs, radiation, heat and novel therapeutics in the fight against prostate cancer.

Study Design

Study Type:
Interventional
Actual Enrollment :
16 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Clinico-pathologic Correlative Study of 3T Magnetic Resonance Spectroscopy in the Localization of Prostate Cancer
Study Start Date :
Jun 1, 2006
Actual Primary Completion Date :
Mar 1, 2008
Actual Study Completion Date :
Mar 1, 2008

Outcome Measures

Primary Outcome Measures

  1. characteristic metabolic pattern of prostate cancer at 3Tesla []

Secondary Outcome Measures

  1. specificity, accuracy, NPV []

  2. PPV of MRS in the detection of prostate cancer []

Eligibility Criteria

Criteria

Ages Eligible for Study:
40 Years and Older
Sexes Eligible for Study:
Male
Accepts Healthy Volunteers:
No
Inclusion Criteria:

  • Histologically verified prostate cancer

  • Patient has opted for surgery

  • Low risk prostate cancer PSA <1 0, Gleason < 7, Stage < T2b

  • No contraindication to MR scanning

  • No prior history of malignancy

  • Fit for surgery

Exclusion Criteria:

  • Nonbiopsied lesion

  • Intermediate or high risk prostate cancer

  • Unfit for surgery

  • Contraindication to MR scanning (i.e. pacemaker, aneurysm clips, claustrophobia)

Contacts and Locations

Locations

Site City State Country Postal Code
1 Cross Cancer Institute Edmonton Alberta Canada T6G 1Z2

Sponsors and Collaborators

  • AHS Cancer Control Alberta
  • Cross Cancer Institute

Investigators

  • Principal Investigator: Matthew Parliament, MD, AHS Cancer Control Alberta

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
AHS Cancer Control Alberta
ClinicalTrials.gov Identifier:
NCT00310479
Other Study ID Numbers:
  • GU-6-0062 / 22281
First Posted:
Apr 4, 2006
Last Update Posted:
Feb 25, 2016
Last Verified:
Mar 1, 2012
Keywords provided by AHS Cancer Control Alberta
Magnetic Resonance Imaging
prostate cancer imaging
3T MRS
functional imaging
Additional relevant MeSH terms:
Prostatic Neoplasms

Study Results

No Results Posted as of Feb 25, 2016